The trial, known as "LIBERATE", will be a randomized study.
The announcement supported a recent statement by the French health minister that ibuprofen may worsen the effects of COVID-19 and should be avoided.
The French government warned that non-steroidal anti-inflammatory drugs (NSAID), such as ibuprofen, could result in "grave adverse effects" in those suffering from COVID-19.